We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
(+18%)
Cap. Flow
+$192M
Cap. Flow
% of AUM
7.6%
Top 10 Holdings %
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$33.4M |
| 2 |
AbbVie
ABBV
|
+$31.2M |
| 3 |
AGN
Allergan plc
AGN
|
+$24M |
| 4 |
Baxter International
BAX
|
+$22.3M |
| 5 |
Gilead Sciences
GILD
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$59.8M |
| 2 |
AGN
Allergan Inc
AGN
|
+$48.5M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$28.5M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$17.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.13% |
| 2 | Real Estate | 3.95% |
| 3 | Financials | 1.4% |
| 4 | Industrials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Baxter International
BAX
$13.8B
| $21.9M | 0.87% |
+588,384
| New | +$22.3M |
|
27
Perrigo
PRGO
$1.43B
| $21.6M | 0.86% |
130,652
+67,700
| +108% | +$10.8M |
|
28
Ventas
VTR
$44.7B
| $21.4M | 0.85% |
256,389
| – | – |
|
|
MDRX
29
DELISTED
Veradigm Inc. Common Stock
MDRX
| $21.3M | 0.84% |
1,778,200
+173,600
| +11% | +$2.12M |
|
30
Jazz Pharmaceuticals
JAZZ
$16.2B
| $20.9M | 0.83% |
120,741
-80,600
| -40% | -$13.8M |
|
|
RCPT
31
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $20.6M | 0.82% |
124,800
+104,400
| +512% | +$13.2M |
|
|
32
Neurocrine Biosciences
NBIX
$18.7B
| $19.9M | 0.79% |
501,150
-499,200
| -50% | -$17.9M |
|
33
iShares Biotechnology ETF
IBB
$9.52B
| $19.8M | 0.78% |
173,010
| – | – |
|
|
GEVA
34
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $19.4M | 0.77% |
198,689
-24,331
| -11% | -$2.58M |
|
35
Thermo Fisher Scientific
TMO
$214B
| $19M | 0.75% |
141,695
+20,700
| +17% | +$2.67M |
|
|
DOC
36
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $18.5M | 0.73% |
1,050,902
+92,900
| +10% | +$1.57M |
|
|
MPT
37
Medical Properties Trust
MPT
$2.81B
| $17M | 0.67% |
1,153,574
+174,800
| +18% | +$2.6M |
|
38
Omega Healthcare
OHI
$15B
| $16.8M | 0.66% |
413,116
+36,700
| +10% | +$1.52M |
|
|
IPXL
39
DELISTED
Impax Laboratories, Inc.
IPXL
| $16.2M | 0.64% |
344,683
| – | – |
|
40
McKesson
MCK
$101B
| $15.3M | 0.61% |
67,862
| – | – |
|
41
Sabra Healthcare REIT
SBRA
$5.38B
| $15.1M | 0.6% |
456,190
+48,300
| +12% | +$1.57M |
|
42
Karyopharm Therapeutics
KPTI
$159M
| $14.6M | 0.58% |
31,798
+22,614
| +246% | +$9.75M |
|
|
ALR
43
DELISTED
Alere Inc
ALR
| $14.6M | 0.58% |
297,901
| – | – |
|
44
Alnylam Pharmaceuticals
ALNY
$27.4B
| $13.6M | 0.54% |
130,195
+68,600
| +111% | +$6.95M |
|
|
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
| $13.4M | 0.53% |
+200,000
| New | +$13.8M |
|
|
ALXN
46
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.4M | 0.53% |
+77,200
| New | +$14M |
|
47
Heron Therapeutics
HRTX
$94.1M
| $12.7M | 0.5% |
873,940
| – | – |
|
48
Verastem
VSTM
$536M
| $12.7M | 0.5% |
104,152
+8,333
| +9% | +$874K |
|
49
Ironwood Pharmaceuticals
IRWD
$614M
| $12.3M | 0.49% |
917,052
| – | – |
|
50
Zimmer Biomet
ZBH
$18.4B
| $12M | 0.48% |
105,369
+23,175
| +28% | +$2.64M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Tekla Capital Management deployed $192M of net new capital in Q1 2015, opening 32 new positions and adding to 30 existing holdings. Its largest new stake was Baxter International: 588,384 shares worth $21.9M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $28.5M trimmed.
- Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
- Tekla Capital Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $33.4M increase.
- Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
- Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
- Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
- Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
- Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.
Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.